Emerging Treatments

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. Hou J et al. Am J Clin Oncol. 2017 Sep 19. doi: 10.1097/COC.0000000000000404. [Epub ahead of print]. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Cavenagh J et al. Br J Cancer. 2017 Sep…

Diagnostic techniques and prognostic indicators

Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Bhutani M et al. Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6. Detection of Circulating Plasma Cells in Multiple Myeloma. Alix-Panabières C et al. Clin Chem. 2017 Sep 18. pii: clinchem.2017.275446. doi: 10.1373/clinchem.2017.275446. [Epub ahead of print]. Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. Sachpekidis C et al. Am J Nucl Med Mol Imaging. 2017 Sep…

Current treatments

Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. Waszczuk-Gajda A et al. J Clin Apher. 2017 Sep 18. doi: 10.1002/jca.21584. [Epub ahead of print]. Autologous hematopoietic cell transplantation for multiple myelomapatients with renal insufficiency: a center for international blood and marrow transplant research analysis. Mahindra A et al. Bone Marrow Transplant. 2017 Sep 18. doi: 10.1038/bmt.2017.198. [Epub…

Complications of myeloma and its treatments

Plasma Cell Infiltration of the Kidney as a Manifestation of Myeloma: A Report of Three Cases. Kaur T et al. Indian J Nephrol. 2017 Sep-Oct;27(5):395-398. doi: 10.4103/ijn.IJN_215_16. Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures. Crowley MP et al. Pathol Oncol Res. 2017 Sep 13. doi: 10.1007/s12253-017-0300-9. [Epub ahead of print]. Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid…

Biology and genetics

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. Wang S et al. Cell Death Dis. 2017 Sep 21;8(9):e3058. doi: 10.1038/cddis.2017.450. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Mroczek S et al. Nat Commun. 2017 Sep 20;8(1):619. doi: 10.1038/s41467-017-00578-5. Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase. Dorasamy MS et al. J…

Supportive treatments

Oncological and functional results of the surgical treatment of vertebral metastases in patients with multiple myeloma. Guzik G et al. BMC Surg. 2017 Aug 23;17(1):92. doi: 10.1186/s12893-017-0288-9. Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports. Lum EL et al. Transplant Direct. 2017 Jul 21;3(8):e200. doi: 10.1097/TXD.0000000000000716. eCollection 2017 Aug. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Lee OL et al. Intern Med…

Related conditions

18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Albano D et al. Eur J Nucl Med Mol Imaging. 2017 Aug 19. doi: 10.1007/s00259-017-3810-5. [Epub ahead of print]. Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series. Cantone E et al. J Med Case Rep. 2017 Aug 10;11(1):219. doi: 10.1186/s13256-017-1382-4. POEMS syndrome in a…

General

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach. Baertsch MA et al. Hematol Oncol. 2017 Aug 25. doi: 10.1002/hon.2473. [Epub ahead of print]. Evolutionary biology of high-risk multiple myeloma. Pawlyn C et al. Nat Rev Cancer. 2017 Aug 24;17(9):543-556. doi: 10.1038/nrc.2017.63. Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients…

Emerging treatments

The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma. Ma H et al. Acta Oncol. 2017 Aug 22:1-7. doi: 10.1080/0284186X.2017.1364868. [Epub ahead of print]. Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. Popat R et al. Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14897. [Epub ahead of…

Diagnostic techniques and prognostic indicators

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Hillengass J et al. Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Mills JR et al. Blood Cancer J. 2017 Aug 25;7(8):e590. doi: 10.1038/bcj.2017.75. Evaluation of pretreatment red cell distribution…